Australia Health

Bio-Gene Technology (ASX:BGT) has commenced a critical acute neurotoxicity study for its flagship nature-derived insecticide, Flavocide.

Osteopore (ASX:OSX), a pioneer in regenerative medicine, announced an exclusive distribution partnership with Medprin Biotech to penetrate the Latin American market.

AVITA Medical (ASX:AVH) reported a "year of stabilisation" with 2025 revenue rising 11% to US$71.6 million.

The Australian Competition and Consumer Commission has formally approved Ramsay Health Care's (ASX:RHC) acquisition of the National Capital Private Hospital.

Cochlear (ASX:COH) booked a 9% dip in underlying profit for H1 FY26, balancing the landmark Nucleus Nexa System launch against fiscal tightening and R&D costs.

Mesoblast (ASX:MSB) unveiled new data at the 2026 tandem meetings of the ASTCT and CIBMTR, reinforcing the efficacy of Ryoncil.

Clinical-stage biotechnology firm Entropy Neurodynamics (ASX:ENP) has announced a major strategic victory with the granting of an Australian patent for its proprietary psychedelic administration method.

Therapeutic antibody developer Patrys (ASX:PAB) appointed Dr. Samantha South as its new CEO, effective Feb. 16.

Pro Medicus (ASX:PME) announced a first-half revenue increase of 28.4% to $124.8 million, while underlying profit before tax rose nearly 30% to $90.7 million.

ECS Botanics (ASX:ECS) announced a landmark strategic partnership with Nimbus Health, a premier German distributor.

Rhythm Biosciences (ASX:RHY) has entered its commercialisation era, announcing the first physician enrollment in its ColoSTAT Access Program.

CSL (ASX:CSL) reports its H1 FY26 financial results, highlighting a resilient US$8.3 billion revenue despite a challenging landscape.